The Real Cost of Ozempic, Wegovy and Other GLP-1 Drugs — With and Without Insurance

Why It Matters

The steep sticker price and uneven insurance coverage create financial barriers that affect millions seeking diabetes or weight‑loss treatment, reshaping payer strategies and pharmaceutical pricing models.

Key Takeaways

• Ozempic list price exceeds $1,000 per month.
• Wegovy costs over $1,300, but insurance can reduce to $25.
• Zepbound list price around $1,086 for 28 days.
• Medicare Part D may cover GLP‑1 drugs starting 2027.
• Novo Nordisk plans up to 50% price cuts in 2027.

Pulse Analysis

The surge in demand for GLP‑1 therapies has turned them into premium commodities, with list prices often surpassing $1,000 for a single month’s supply. While these figures capture headlines, the real cost to consumers hinges on insurance design. Many health plans place these drugs in higher tiers, requiring patients to meet deductibles or pay coinsurance, yet negotiated discounts and pharmacy‑benefit managers can shrink the net price to a modest $25‑$50 copay. This disparity underscores the importance of price transparency tools like GoodRx, which help patients gauge their true out‑of‑pocket expense.

Insurance nuances further complicate access. Some policies cover GLP‑1 agents only for diabetes, while others extend benefits to weight‑management indications, often contingent on prior authorization. The Centers for Medicare & Medicaid Services (CMS) is preparing to broaden coverage, with Medicaid eligibility slated for May and Medicare Part D inclusion expected in early 2027 under the BALANCE Model. Meanwhile, tax‑advantaged accounts such as FSAs and HSAs provide additional avenues for patients to offset recurring costs, emphasizing the need for comprehensive financial planning beyond the initial prescription price.

Looking ahead, the market is poised for a pricing shift. Novo Nordisk’s announced plan to slash list prices by up to half in 2027 aims to make GLP‑1 drugs more accessible and could pressure competitors to follow suit. Lower prices may accelerate adoption, expand the therapeutic pool for obesity and diabetes, and reshape payer negotiations. For providers, understanding these evolving cost structures is critical to advising patients and managing long‑term treatment budgets.